分子降解剂:对小分子诱导的蛋白质降解策略的全面审查
Deepanshu Sindhwani1, Kaushal Arora2, Pankaj Kumar3,4
1Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Current protein & peptide science
|June 20, 2025
概括
分子降解剂,包括PROTACs和分子,提供了一种消除致病蛋白质的新方法. 本综述分析了它们的设计,机制和精密医学中的治疗潜力.
科学领域:
- 生物化学和药理学 生物化学和药理学
- 药物发现和开发 药物发现和开发
背景情况:
- 分子降解剂是一种新的治疗类.
- 它们选择性地消除引起疾病的蛋白质,包括以前无法治疗的点.
- 关键的例子包括蛋白质溶解向金马 (PROTACs) 和分子.
研究的目的:
- 批判性地分析分子降解剂的设计和机制复杂性.
- 审查E3结合酶选择和三元复合体形成方面的进展.
- 检查针对性蛋白质降解的治疗应用和挑战.
主要方法:
- 使用主要科学数据库 (PubMed,Google Scholar,Science Direct等) 进行全面的文献审查. ) 的情况.
- 分析乌比奎介导的蛋白质降解途径.
- 评估结构动态,临床前数据和临床挑战.
主要成果:
- 对PROTACs,分子和SNIPERs进行了详细的检查.
- 讨论新的非正规降解方法及其临床前成功.
- 在瘤学,神经退行性疾病和传染病中确定治疗应用.
结论:
- 分子降解剂对药物发现和精密医学具有变革潜力.
- 需要进一步的研究来解决耐药性机制,安全性和药物动力学限制.
- 针对性蛋白质降解的创新是由了解降解剂的设计和功能驱动的.
相关概念视频
Regulated Protein Degradation
2.6K
2.6K
The Proteasome
1.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K
Covalently Linked Protein Regulators
7.4K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
7.4K
Protein-protein Interfaces
13.7K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.7K
Export of Misfolded Proteins out of the ER
3.9K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.9K


